• The vaccine uses adenovirus serotype 26 as a vector encoding a prefusion stabilized SARS-CoV-2-spike immunogen, a protein which mediates entry of the SARS-CoV-2 into host cells.

• A single immunization induced a neutralizing antibody response and complete protection against SARS-CoV-2 in 5 out of 6 rhesus macaques.

• The phase 1/2a clinical trial is now underway in Belgium and the United States with phase 3 starting in September if results are positive.